TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Clinical Trial on Hemoglobin Dose and Patient Matching

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients receiving red cell transfusions or expected to receive one or more red cell transfusions~* Patients over 16 years of age~* Patients for whom height and weight information is available~* Patients who have consented to participate~Exclusion Criteria:~* Patients who are hemodynamically unstable (ongoing bleeding or hemolysis)~* Patients with a known hemolytic anemia (congenital or acquired)~* Patients with a positive Direct Antiglobulin Test (DAT)~* Patients for whom informed consent has not been obtained~* Patients where the hemoglobin concentration increment target is above 2g/dl.~* Patients with auto- or alloantibodies against RBCs.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hemoglobin dose (Type: EXPERIMENTAL): Intervention: Calculated red blood cell transfusion
- Standard treatment (Type: ACTIVE_COMPARATOR): Intervention: Standard red blood cell transfusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Results of Tc99m-Maraciclatide Scintigraphy in Subjects With Diabetes Mellitus and Heart Failure With Preserved Left Ventricular Ejection Fraction

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The subject is between 18 and 80 years of age.~* The subject was diagnosed with DM type 2 based upon accepted clinical criteria and currently takes at least one diabetes medication.~* For HF subjects: The subject was diagnosed with HF with preserved EF within the previous 1 year, at which time LVEF was determined to be ≥45%.~* For comparison subjects: The subject was determined to have diastolic dysfunction on EKG within the previous year and currently has no signs or symptoms of HF.~* The subject has been clinically stable for at least 7 days prior to the study imaging procedures (e.g., not experiencing continuing chest pain, hemodynamic instability, worsening HF symptoms, or clinically significant arrhythmia).~Exclusion Criteria:~* The subject had an acute myocardial infarction within the past 30 days.~* The subject had a cardiac revascularization (e.g., percutaneous transluminal coronary angiography \[PTCA\], percutaneous coronary intervention (PCI), or coronary artery bypass graft \[CABG\]) within the past 30 days.~* The subject has severe renal dysfunction.~* The subject is claustrophobic or has a movement disorder that prevents him/her from lying still in a supine position for up to 20 minutes at a time.~* The subject has participated in a research study using ionizing radiation in the previous 12 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Tc99m-Maraciclatide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Extension Study of BMN 044 in Duchenne Muscular Dystrophy (DMD)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects previously treated with BMN 044 or a comparator treatment in a BMN 044 Sponsored Study or Investigator Initiated Trial and who are not eligible for another ongoing BMN 044 study.~* Continued use of glucocorticosteroids for a minimum of 60 days prior to study entry with a reasonable expectation that the subject will remain on glucocorticosteroids for the duration of this study.~* Willing and able to comply with all study requirements and procedures.~* Willing and able to provide written, signed informed consent, or in the case of subjects under the age of 18 years(or 16 years, depending on the region), provide written assent (if required) and written informed consent by a legally authorized representative after the nature of the study has been explained, and prior to the conduct of any research-related procedures.~Exclusion Criteria:~* Subjects who have previously been treated with BMN 044 who had a serious adverse experience or met safety stopping criteria, that remains unresolved, which in the opinion of the Investigator could have been attributable to BMN 044.~* History of significant medical disorder which may confound the interpretation of safety data~* Acute illness within 4 weeks prior to the first dose of BMN 044 (Week 1) which may interfere with the measurements.~* Symptomatic cardiomyopathy.~* Baseline aPTT above the upper limit of normal (ULN).~* Baseline platelet count below the lower limit of normal (LLN).~* Use of anti coagulants, anti thrombotics or anti platelet agents within 28 days of the baseline visit.~* Prior use of any investigational product (other than BMN 044) or investigational medical device must be discussed with the Medical Monitor prior to screening.~* Current or history of drug and/or alcohol abuse.

- Gender: MALE
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BMN 044 IV 6 mg/kg (Type: EXPERIMENTAL): Weekly intravenous (IV) dosing with 6 mg/kg
- BMN 044 IV 9 mg/kg (Type: EXPERIMENTAL): Weekly intravenous (IV) dosing with 9 mg/kg
- BMN 044 SC 6 mg/kg (Type: EXPERIMENTAL): Weekly subcutaneous (SC) dosing with 6 mg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Two Embryo Transfer Catheters in Patients Undergoing in Vitro Fertilization and Embryo Transfer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~(i) ET in the fresh cycle (ii) Age \<43 year (iii) Normal uterine cavity shown on ultrasound scanning~Exclusion Criteria:~(i) Three previous IVF cycles (ii) Natural IVF or IVM cycles (iii) Presence of hydrosalpinx on pelvic scanning (iv) Transfer of grade 5 embryos (v) Blastocyst transfer (vi) Use of donor oocytes (vii) Pre-implantation genetic diagnosis and (viii) Previously joined in the same study

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: 42 Years
- Healthy Volunteers: f

Study Arms:
- Protective catheter group (Type: EXPERIMENTAL): Protective catheter group uses Guardia™ Pro Protective ET catheter from Cook.
- Conventional catheter group (Type: ACTIVE_COMPARATOR): Conventional catheter group uses Sydney IVF catheter from Cook.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Bariatric Surgery and Guided Self-help for Binge Eating Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Obese (BMI \>28 kg/m2)~* Pursuing bariatric surgery~Exclusion Criteria:~* Any illnesses which make the patient unsuitable~* If the patient is taking any medication which makes them unsuitable~* If the patient is pregnant or breast feeding~* If the patient has donated blood in the last three months~* If the patient has a history of alcoholism or substance dependency within the last 5 years~* If the patient has a history of major haematological, renal, gastrointestinal, hepatic, respiratory, cardiovascular or psychiatric disease or other illness or use of any medications, including over the counter products, which, in the opinion of the investigators would either interfere with the study or potentially cause harm to the volunteer~* If the patient has any medical or psychological condition or social circumstances which would interfere with their ability to participate reliably in the trial~* If the patient is without access to a telephone~* If the patient is currently receiving or intends to receive treatment with an investigational drug within the next 2 months If the patient is currently receiving or intends to receive treatment for binge eating~* If the patient currently suffers with severe depression, as indicated by a Beck Depression Inventory Score greater than 28

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Guided Self Help (Type: EXPERIMENTAL): Guided Self Help intervention to reduce binge eating
- Treatment As Usual (Type: PLACEBO_COMPARATOR): No intervention for binge eating (treatment as usual in the form of bariatric surgery)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Alpers Huttenlocher Natural History Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All individuals of any age with confirmed Alpers Huttenlocher Syndrome (AHS) or siblings of confirmed AHS patients are eligible to participate. AHS requires the presence of polymerase gamma 1 (POLG) pathological mutations, either homozygous or compound heterozygote mutations, and the presence of epilepsy and either, developmental regression or hepatopathy. If POLG mutations are not demonstrated, AHS requires the presence of refractory seizures, developmental regression, and hepatopathy as well as two or more other clinical and laboratory findings including elevated cerebrospinal fluid (CSF) protein, neuroimaging showing lactate peaks, reduced N-acetyl aspartate with hyperintensities on T2/FLAIR in the thalamus and posterior head regions, optic atrophy/cortical blindness, quantitative mtDNA reduction (\>30% ) in muscle and/or liver, non-specific electron transport chain (ETC) enzyme deficiencies.~* All patients must agree to participate in the North American Mitochondrial Disease Consortium (NAMDC) Clinical Registry~Exclusion Criteria:~* Patient does not have confirmed AHS and is not the sibling of a patient with confirmed AHS~* Not willing to participate in the NAMDC clinical Registry

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Patients with Alpers-Huttenlocher (Type: None): Patients confirmed to have Alpers Huttenlocher Syndrome
- Siblings (Type: None): Siblings of patients with Alpers Huttenlocher Syndrome

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study of Everolimus in de Novo Renal Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Renal transplant patients~* Age between 18 and 85 years~* Recipients of living or deceased donors~* Donor under the age of 85 years~* Panel Reactivity Antibodies (PRA) over or equal to 30%~* 4-5 months post-transplant~* CNI-based immunosuppressive regimen~* Stable graft function (creatinine lower than 2.0 mg/dl)~* No currently acute rejection~* Proteinuria lower than 800mg/d~* No laboratory or physical clinically significant signs presented for the last 2 months before screening.~Exclusion Criteria:~* Recipient of multiple organs~* Recipient with a history of focal segmental glomerulosclerosis or membranous glomerulonephritis~* Presence of uncontrolled hypercholesterolemia (≥350 mg/dL)hypertriglyceridemia (over or equal to 500 mg/dL)~* Patients with eGFR lower than 40 ml/min/1.73m2~* Evidence of acute rejection within 2 months before screening~* Thrombocytopenia (lower than 75,000/mm3)~* Neutropenia (lower than 1,500/mm3)~* Leukocytopenia (lower than 2500/mm3)~* Anemia (hemoglobin lower than 6.0g/dL)~* Severe liver disease (including transaminases or bilirubin equal or over 3 times normal)~* Proteinuria over 800mg/dL~* Systemic infection or pneumonia (active infection)~* Positive for Hepatitis B, Hepatitis C or HIV.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): 35 patients using Cyclosporin or Tacrolimus (C0=100-200/5-10ng/mL)+ Myfortic® 1440mg/dia + Steroids.~Medications will be administered orally, twice a day
- Intervention (Type: ACTIVE_COMPARATOR): 35 randomized Patients Converted to Certican® (Everolimus C0=6-10 ng/mL) + Myfortic® 1440mg/day + Steroids.~On the day of conversion (day 1), 2 mg everolimus will be introduced in the morning and at night, as morning dose of CsA or Tac will be maintained and evening dose of CsA or Tac will be reduced by 50%.~In two days, 2 mg everolimus will be associated with 50% of CsA or Tac original dosage, both in the morning and evening. After that, everolimus dose will be adjusted to achieve a C0 target level of 6-10 ng/mL. Once target levels of everolimus are met, the CNI drug will be suspended.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* ECOG 0 or 1~* Primary or metastatic tumor onfirmed as triple negative~* Measurable disease per RECIST version 1.1~* normal organ function, including bone marrow function, renal function, liver function, and cardiac function~* Two or more prior chemotherapy~* signed and dated an informed consent form~* Life expectancy of at least 12 weeks~Exclusion Criteria:~* Pregnant or breast feeding~* ECOG score ≧2~* Uncontrolled medical problems~* Hepatic, renal, or bone marrow dysfunction as detailed above~* Concurrent malignancy or history of other malignancy within the last five years except as noted above~* Patients were unable or unwilling to comply with program requirements

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Icotinib (Type: EXPERIMENTAL): Icotinib 125 mg BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Low Back Study to Compare Traditional Physical Therapy With Combined Therapy Protocol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* MRI of the lumbar spine showing symptoms and severity to qualify for surgery~* 25 to 65 years of age~* Diagnosis of low back pain for 3-12 months~* Potential surgical candidates but not mandatory~Exclusion Criteria:~* any medical or physical conditions deemed unacceptable by the participants physician or health care provider~* Evidence of progressive or debilitative medical conditions i.e. metastatic cancer, major stroke, crippling arthritis, unstable angina, orthostatic hypotension, hemiplegia, multiple sclerosis or Parkinson's disease.~* Any condition that would preclude the additional burden of a repeat MRI or preclude active involvement in the protocol or physical therapy~* Active use of tobacco products~* Prior back surgery~* Pregnancy

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Endoscopic Posterior Mesorectal Resection in T1 Rectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Stage T1 (only)~* Over 18 years old~* Patient's consent~* Previous R0 resection of rectal tumor~Exclusion Criteria:~* Metastases (M1)~* Neoadjuvant chemotherapy or radiotherapy~* Meta- or synchronous tumors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment arm (Type: EXPERIMENTAL): endoscopic posterior mesorectal resection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Free, informed, express and written.~* Diagnosis of native kidney primary IgA glomerulonephritis biopsy-proven~* First kidney transplantation (one kidney)~Exclusion Criteria:~* Panel Reactive Antibody (PRA PRA global or class I or class II PRA) over 50% on a serum before transplantation~* Multi-organ graft~* Transplants using donor limits or sub-optimal: donor age ≥ 70 years, donors in the study BIGRAS or taken heart beating donors (tested on computer infusion) or other restriction factors~* IgA glomerulonephritis secondary to HSP (Henoch-Schonlein purpura) or Systemic Lupus Erythematosus (SLE) or alcoholic cirrhosis~* History of cancer older than 5 years or with advanced cancer, but except for non-recurrent skin cancers~* Infectious diseases scalable: tuberculosis, HIV, Hepatitis B virus or Hepatitis C virus infection with viral replication and / or chronic hepatitis~* Allergy to rabbit proteins~* Severe thrombocytopenia (\<50,000 platelets/ul)~* Bacterial infection, viral and fungal uncontrolled therapeutically~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ATG-F (Type: EXPERIMENTAL): The ATG-Fresenius® is administered by slow infusion over four hours after antihistamine (2 bulbs Polaramine® IV) and intravenous methylprednisolone (minimum 30mg); it is started on day 0 prior to surgery at doses of 4 mg / kg, and then continued to day 1, day 2 to 4mg / kg, then day 3, day 4 at the dose of 3 mg / kg
- Simulect (Type: ACTIVE_COMPARATOR): The anti CD25 (basiliximab, Simulect®) is administered intravenously before surgery of renal transplantation (Day 0 and Day + 4 (1 ampoule of 20 mg x 2 times).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Genetic Substudy Associated With the Avastin (Bevacizumab) Study MO19390 in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* participating in, and meeting all inclusion/exclusion criteria of, MO19390.~Exclusion Criteria:~* not meeting the inclusion/exclusion criteria of MO19390.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Transcutaneous Electrical Nerve Stimulation for Overactive Bladder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who are clinically diagnosed with urge incontinence, defined as urinary leakage associated with a sudden, strong desire to pass urine that is difficult to defer.~* Patients with urge predominant mixed incontinence.~* Patients will need to have answered at Yes to leakage related to feeling urgency on the UDI 6 questionnaire.~* Female~* Over 18 years of age.~* English speaking who are able to give informed consent to participate in the study.~* Patients who have four urinary incontinence episodes.~Exclusion Criteria:~* Stress incontinence desiring surgical management.~* Previous treatment of refractory urge incontinence such as PTNS, SNS, or Intradetrusor onabotulinumtoxin A injections.~* Neurological conditions affecting continence such as multiple sclerosis, a history of spinal shock within the past year, or neurologic impairment requiring a wheelchair.~* Urethral diverticulum.~* Daily catheterization due to urinary retention.~* The use of anticholinergic medications for less than 6 weeks.~* Patients who have pacemakers in place.~* Patients with limited mobility requiring a wheelchair.~* Elevated PVR \> 200 cc~* Untreated urinary tract infection, defined as symptoms and a urine culture with greater than 100,000 cfu/ ml within the last 1 month prior to treatment.~* Uncorrected Stage 3 prolapse.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Tibial Nerve (Type: ACTIVE_COMPARATOR): Transcutaneous electrical stimulation will be placed on the posterior tibial nerve.
- Parasacral (Type: ACTIVE_COMPARATOR): Transcutaneous electrical stimulation will be placed on the lower back near the s3 foramina.
- Shoulder (Type: SHAM_COMPARATOR): Transcutaneous electrical stimulation will be placed on the shoulder.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues